Finch Therapeutics Group IncOTC Pink - Current Information:FNCH
- LAST PRICE11.2000
- TODAY'S CHANGE (%)-0.8000 (-6.6667%)
- Bid / Lots8.4000/ 1
- Ask / Lots12.6400/ 1
- Open / Previous Close11.6300 / 12.0000
- Day Range
- 52 Week Range
- Volume4,385
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | FNCH |
|---|---|---|
| 09:42 ET | 100 | 11.63 |
| 10:56 ET | 3434 | 11.63 |
| 12:42 ET | 535 | 11.2 |
Oct 21, 2024
Finch Announces Delisting from Nasdaq and SEC Deregistration, from 7:30AM ET on Monday Oct 21, 2024 by Dow Jones
7:30AM ET on Monday Oct 21, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Finch Therapeutics Group Inc | 18.0M | -1.3x | --- |
Cognition Therapeutics Inc | 18.5M | -0.5x | --- |
NanoViricides Inc | 17.2M | -1.8x | --- |
CytoMed Therapeutics Ltd | 25.1M | -11.0x | --- |
NeuroBo Pharmaceuticals Inc | 19.1M | -0.5x | --- |
Tenax Therapeutics Inc | 16.6M | -0.2x | --- |
Company Information
Finch Therapeutics Group, Inc. is a microbiome technology company with a portfolio of intellectual property and microbiome assets. It is focused on realizing the value of its intellectual property estate and other assets, while supporting the advancement of its microbiome technology through partnerships and collaborations. It has an intellectual property estate, including more than 113 issued U.S. and foreign patents with relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. Its assets include CP101, an orally administered microbiome candidate designed for the prevention of recurrent C. difficile infection (CDI), with positive clinical data from a Phase II randomized, placebo-controlled trial and a Phase II open-label trial, and pre-clinical assets that are designed to target ulcerative colitis, Crohn’s disease, and autism spectrum disorder. Additionally, it has also developed a biorepository of strains and samples.
Contact Information
- Headquarters
- 75 State Street, Suite 100BOSTON, MA, United States 02109
- Phone
- 617-229-6499
- Fax
- 302-636-5454
Executives
- Independent Non-Executive Chairman of the Board
- Christian Lange
- President, Chief Executive Officer, Secretary
- Matthew Blischak
- Chief Financial Officer
- Lance Thibault
- Independent Director
- Domenic Ferrante
- Independent Director
- Christopher Shumway
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $18.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.6M |
Finch Therapeutics Group Inc does not pay a dividend. | |
Beta | 1.28 |
EPS | $-8.82 |
Book Value | $14.25 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
